Skip to main content
. 2020 Apr 28;10(5):682. doi: 10.3390/biom10050682

Figure 3.

Figure 3

Enforced expression of ADAMTS-15 and ADAMTS-15EA in prostate cancer cell lines. (A) Structure of ADAMTS-15 and its catalytically inactive mutant, with domains identified in the key, the position of the inactivating E to A mutation in the metalloproteinase domain highlighted in red, and the C-terminal Myc/His tag indicated. (B–D) Western blot analysis of representative stable LNCaP (B,C) and PC-3 (D,E) transfectant clones as indicated containing empty pcDNA3.1 (Con) or pcDNA3.1 expressing ADAMTS-15 (TS-15) (B,D) or ADAMTS-15EA (TS-15EA) (C,E) with anti-Myc antibody to detect expression of tagged ADAMTS-15 and ADAMTS-15EA. Note the presence of zymogen (upper bands) and mature forms (lower bands) in each case. Anti-GAPDH was used as a loading control, and the relative position of size markers indicated.